Phase I Study of Vorinostat and Sorafenib in Advanced Cancer

Part of paid clinical trials in Aurora, Colorado.

Sponsor
University of Colorado, Denver
Study ID
NCT00635791
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Sorafenib — DRUG
    Given by mouth
  • Vorinostat — DRUG
    Given by mouth

Study Details

This phase I trial studies the side effects and best dose of giving vorinostat and sorafenib tosylate together in treating patients with kidney or non-small cell lung cancer. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib tosylate may stop the growth of solid tumors by blocking blood flow to the tumor. Giving vorinostat together with sorafenib tosylate may kill more tumor cells.

Key Dates

Start date
Mar 31, 2008
Status verified
Jun 2013
Primary completion
Oct 31, 2011
Completion
Mar 31, 2012

Study Design

Enrollment
36 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Sorafenib tosylate and vorinostat
    Patients receive sorafenib tosylate by mouth twice a day on days 1-21 and vorinostat by mouth every day on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Maximum tolerated dose (MTD) [ Time Frame: Up to 21 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Colorado Cancer CenterAuroraColorado80045-

Find similar trials in Aurora, CO

By condition
Kidney cancer
By specialty
OncologyUrology
By research site
University of Colorado Cancer Center· Aurora, CO

Related Studies